Skip to main content
. 2021 Mar 29;27(2):22. doi: 10.1007/s11948-021-00300-1

Fig. 3.

Fig. 3

Schematic illustration of a (simplified) biotechnology’s development process, and the iterative character of Safe-by-Design. The parts from ‘scale-up’ onwards (in white) are left out of consideration as the focus within this study is on experimental design choices and nog upscaling or market implementation